Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 0/1 Study of NST-628 in Participants With Recurrent Grade 4 Glioma Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With Pharmacodynamic (PD) Triggered Expansion Cohort

NCT07784985 is registered in ClinicalTrials.gov with Nader Sanai as lead sponsor.

NCT NCT07784985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07784985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 0/1 Study of NST-628 in Participants With Recurrent Grade 4 Glioma Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With Pharmacodynamic (PD) Triggered Expansion Cohort
Lead sponsor
Nader Sanai
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
July 31, 2028
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma, recurrent high grade, grade 4 malignant glioma